title: Comparison of cryopreservation outcome with human pronuclear stage oocytes obtained by the GnRH antagonist, cetrorelix, and GnRH agonists.
abstract: This retrospective study was performed to examine the implantation and pregnancy rates of frozen-thawed pronuclear stage oocytes obtained with the use of a GnRH antagonist, Cetrorelix (Cetrotide((R)) ASTA-Medica, Frankfurt/M, Germany) used in a multidose protocol with hMG, and to compare these results with those obtained after a conventional long GnRH analogue protocol (Decapeptyl-Depot, Ferring, Kiel, Germany). The study population consisted of 31 infertile couples with frozen-thawed pronuclear stage oocytes after ICSI treatment using the GnRH antagonist Cetrorelix (Cetrorelix((R))) and 31 infertile couples with frozen-thawed pronuclear stage oocytes after ICSI treatment using the long GnRH analogue protocol. Patients underwent ICSI after down regulation with a GnRH agonist (Decapeptyl) and stimulation with hMG, or a GnRH antagonist (Cetrorelix) and hMG. The supernumerary pronuclear stage oocytes were cryopreserved and transferred in a later mildly stimulated cycle. The implantation and pregnancy rates for frozen-thawed pronuclear stage oocytes derived from the GnRH antagonist compared with the GnRH agonist were 3.26% versus 3.73% (P=1.0000) and 8.33% versus 10.25% (P=1.0000), respectively. To our knowledge we report here the first pregnancies obtained by the transfer of cryopreserved pronuclear stage embryos generated from ICSI using a GnRH antagonist in the collecting cycle. The use of Cetrorelix in a multiple dose protocol in combination with hMG does not demonstrate a negative effect on viability, implantation potential or pregnancy outcome as compared to 2PN conceptuses obtained from a long GnRH agonist-hMG protocol.
authors.affiliation: Democritus University of Thrace, Faculty of Medicine, Alexandroupolis, Greece.
authors.forename: N
authors.initials: N
authors.lastname: Nikolettos
authors.forename: S
authors.initials: S
authors.lastname: Al-Hasani
authors.forename: R
authors.initials: R
authors.lastname: Felberbaum
authors.forename: L C
authors.initials: LC
authors.lastname: Demirel
authors.forename: H
authors.initials: H
authors.lastname: Riethmüller-Winzen
authors.forename: T
authors.initials: T
authors.lastname: Reissmann
authors.forename: B
authors.initials: B
authors.lastname: Schöpper
authors.forename: R
authors.initials: R
authors.lastname: Sturm
authors.forename: K
authors.initials: K
authors.lastname: Diedrich
mesh_terms: D000022:Abortion, Spontaneous; D015925:Cryopreservation; D010064:Embryo Implantation; D004624:Embryo Transfer; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage* / Q000819:agonists / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors*; D006727:Hormone Antagonists / Q000008:administration & dosage*; D006801:Humans; D007246:Infertility / Q000628:therapy; D008596:Menotropins / Q000008:administration & dosage; D009865:Oocytes / Q000502:physiology*; D011247:Pregnancy; D011256:Pregnancy Outcome; D012189:Retrospective Studies; D020554:Sperm Injections, Intracytoplasmic; D017329:Triptorelin Pamoate / Q000008:administration & dosage
chemical_list: D006727:Hormone Antagonists; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D008596:Menotropins; C062876:cetrorelix